Related Experiment Video
Updated: May 30, 2026
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
Identification of a natural compound by cell-based screening that enhances interferon regulatory factor-1 activity
Jinbo Gao1, Yujun Wang, Quanhua Xing
1Department of Surgery, Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, PR China.
Abstract:
The transcription factor interferon regulatory factor-1 (IRF-1) is induced by many tumor-suppressive stimuli and can mediate antiproliferative and proapoptotic effects in cancer cells. Thus, identifying agents that enhance IRF-1 activity may be an effective approach to cancer therapy. A cell-based screening assay was developed to identify extracts and compounds that could enhance IRF-1 activity, using an IRF-1-dependent luciferase reporter cell line. Through this approach, we identified a natural product extract and a known active component of this extract, baicalein, which causes a marked increase in IRF-1-dependent reporter gene expression and IRF-1 protein, with modulation of known IRF-1 targets PUMA and cyclin D1. Baicalein causes suppression of growth in vitro in multiple cancer cell lines in the low micromolar range. IRF-1 plays a role in this growth suppression as shown by significant resistance to growth suppression in a breast cancer cell line stably transfected with short hairpin RNA against IRF-1. Finally, intraperitoneal administration of baicalein by repeated injection causes inhibition of growth in both xenogeneic and syngeneic mouse models of cancer without toxicity to the animals. These findings indicate that identifying enhancers of IRF-1 activity may have utility in anticancer therapies and that cell-based screening for activation of transcription factors can be a useful approach for drug discovery.
Insights
Researchers discovered baicalein, a natural compound that enhances interferon regulatory factor-1 (IRF-1) activity. This enhancement suppressed cancer cell growth in vitro and in vivo, suggesting a new avenue for cancer therapy development.
Area of Science:
- Molecular Biology
- Cancer Research
- Drug Discovery
Background:
- Interferon regulatory factor-1 (IRF-1) is a transcription factor with tumor-suppressive properties.
- Enhancing IRF-1 activity is a potential strategy for cancer therapy.
- Natural products are a promising source for novel therapeutic agents.
Purpose of the Study:
- To develop a cell-based screening assay to identify agents that enhance IRF-1 activity.
- To investigate the potential of natural product extracts and compounds as IRF-1 enhancers for cancer therapy.
Main Methods:
- Development of an IRF-1-dependent luciferase reporter cell line for high-throughput screening.
- Identification and characterization of active compounds from natural product extracts.
- In vitro assessment of baicalein's effects on cancer cell growth and IRF-1 targets (PUMA, cyclin D1).
- In vivo evaluation of baicalein efficacy in mouse cancer models.
Main Results:
- A natural product extract and its component, baicalein, were identified as potent enhancers of IRF-1 activity.
- Baicalein significantly increased IRF-1-dependent reporter gene expression and IRF-1 protein levels.
- Baicalein demonstrated in vitro growth suppression of multiple cancer cell lines and modulated IRF-1 targets.
- IRF-1 was shown to be crucial for baicalein's growth-suppressive effects.
- Baicalein inhibited tumor growth in mouse models without observable toxicity.
Conclusions:
- Baicalein enhances IRF-1 activity, leading to anticancer effects.
- IRF-1 activation is a viable therapeutic strategy for cancer treatment.
- Cell-based screening assays are effective for discovering transcription factor-activating drugs.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
02:15Experimental RNAi